<DOC>
	<DOCNO>NCT00309140</DOCNO>
	<brief_summary>This study collect basic safety data patient cancer treat enzastaurin . This study open public . The purpose study extend clinical experience patient complete enzastaurin therapy per clinical pharmacology biopharmaceutics study conduct Eli Lilly Company may benefit continued enzastaurin therapy .</brief_summary>
	<brief_title>An Open Label Study Oral Enzastaurin Patients With Cancer</brief_title>
	<detailed_description />
	<criteria>You must previously participate finish study JCAV , JCAY enzastaurin clinical pharmacology biopharmaceutics study . If cancer treatment ( chemotherapy , radiation , anticancer hormone therapy ) , must complete least 4 week ago enroll study . You must cancer therapy exist prolong life . This may include patient treated , stable brain cancer . You must lesions ( area cancer body ) doctor either measure detect . You either must able become pregnant , ( 've surgery [ `` tube tie '' hysterectomy ] , 've go menopause , 've previous radiation cancer make sterile ) potential become pregnant must reduce use approve birth control method ( include intrauterine barrier device ) 3 6 month follow study . You either male female , must least 18 year old . You must receive treatment within last 30 day drug enzastaurin still experimental ( mean receive approval prescribe , except clinical trial ) . You must pregnant breastfeeding . You must central nervous system ( CNS ) tumor ( tumor brain spinal cord ) . ( However , patient stable CNS tumor take steroid medication may include . ) You must another serious disorder , include active infection interfere participation study . You must second cancer addition primary cancer . Patients adequately treat skin cancer another cancer past , cancer free 2 year , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>